Literature DB >> 2301926

Inhibition of mononuclear phagocytes reduces ischemic injury in the spinal cord.

D Giulian1, C Robertson.   

Abstract

Transient ischemia to the lumbar and sacral sections of the spinal cord of rabbit leads to a deterioration in neurological function that usually worsens 24 to 48 hours after injury. This decline in movement of the hindlimbs develops simultaneously with the appearance of mononuclear phagocytes in the gray matter of injured neural tissue. Chloroquine and colchicine inhibit phagocytic and secretory functions in mononuclear phagocytes. When given up to 6 hours after an induced ischemic lesion in rabbit, this drug combination decreased the number of mononuclear phagocytes found within the gray matter of damaged spinal cord, improved the recovery of function of the hindlimbs and bladder, preserved spinal somatosensory evoked potentials, and promoted the survival of motor neurons. In contrast, the glucocorticoid dexamethasone, a weak inhibitor of mononuclear phagocytes in vivo, did not reduce the number of inflammatory cells in the spinal cord and did not improve motor and bladder functions. The suppression of mononuclear phagocytes soon after ischemic injury may offer a new approach in the treatment of vascular disease in the central nervous system.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2301926     DOI: 10.1002/ana.410270107

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  48 in total

1.  The developmental loss of the ability of Purkinje cells to regenerate their axons occurs in the absence of myelin: an in vitro model to prevent myelination.

Authors:  Lamia Bouslama-Oueghlani; Rosine Wehrlé; Constantino Sotelo; Isabelle Dusart
Journal:  J Neurosci       Date:  2003-09-10       Impact factor: 6.167

Review 2.  Debate: "is increasing neuroinflammation beneficial for neural repair?".

Authors:  Keith A Crutcher; Howard E Gendelman; Jonathan Kipnis; J Regino Perez-Polo; V H Perry; Phillip G Popovich; Lynne C Weaver
Journal:  J Neuroimmune Pharmacol       Date:  2006-05-23       Impact factor: 4.147

Review 3.  Inflammation and its role in neuroprotection, axonal regeneration and functional recovery after spinal cord injury.

Authors:  Dustin J Donnelly; Phillip G Popovich
Journal:  Exp Neurol       Date:  2007-06-30       Impact factor: 5.330

4.  Pathology dynamics predict spinal cord injury therapeutic success.

Authors:  Cassie S Mitchell; Robert H Lee
Journal:  J Neurotrauma       Date:  2008-12       Impact factor: 5.269

5.  Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord.

Authors:  Kristina A Kigerl; John C Gensel; Daniel P Ankeny; Jessica K Alexander; Dustin J Donnelly; Phillip G Popovich
Journal:  J Neurosci       Date:  2009-10-28       Impact factor: 6.167

Review 6.  Inflammation and axonal regeneration.

Authors:  P M Richardson; X Lu
Journal:  J Neurol       Date:  1994-12       Impact factor: 4.849

Review 7.  Glucocorticoids in Alzheimer's disease. The story so far.

Authors:  P S Aisen; G M Pasinetti
Journal:  Drugs Aging       Date:  1998-01       Impact factor: 3.923

8.  Quantitative analysis of cellular inflammation after traumatic spinal cord injury: evidence for a multiphasic inflammatory response in the acute to chronic environment.

Authors:  Kevin D Beck; Hal X Nguyen; Manuel D Galvan; Desirée L Salazar; Trent M Woodruff; Aileen J Anderson
Journal:  Brain       Date:  2010-01-19       Impact factor: 13.501

9.  Specific domains of beta-amyloid from Alzheimer plaque elicit neuron killing in human microglia.

Authors:  D Giulian; L J Haverkamp; J H Yu; W Karshin; D Tom; J Li; J Kirkpatrick; L M Kuo; A E Roher
Journal:  J Neurosci       Date:  1996-10-01       Impact factor: 6.167

10.  Glycine: an important potential component of spinal shock.

Authors:  R K Simpson; C S Robertson; J C Goodman
Journal:  Neurochem Res       Date:  1993-08       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.